Jul 21, 2025
Eight years after its founding, partly backed by AstraZeneca, Dizal Pharmaceuticals has secured its first FDA approval, receiving accelerated clearance for ZEGFROVY (sunvozertinib)—now the only FDA-approved oral therapy for a rare subset of non-small cell lung cancer (NSCLC). The treatment is indicated for U.S. ...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper